This protective effect of MaR1 in different models of experimental colitis seems to be mediated by the inhibition of NF-κB activity, the reduction of inflammatory mediators, and the promotion of the anti-inflammatory macrophage M2 phenotype [31]. Here, NFKB1 is linked to colitis.